NCT04368273

Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.

Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University Third Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of anti-PD-1 (toripalimab) combined with cisplatin concurrent IMRT for locally advanced cervical cancer.

Detailed description

The dose of toripalimab injection (pd-1 antibody) was 240mg/d, d1, i.v. every 14d, totally 4 cycles (56 days) Concurrent chemoradiotherapy: Cisplatin 40 mg/m2 i.v., d1, administered once a week; Radiotherapy: pelvic intensity modulated radiotherapy, prescription dose DT: 50.4gy /2Gy/28f;After intraluminal irradiation DT: 30-36 Gy/6Gy/5-6f 2f/w, complete the radiotherapy within 56 days. Complete at least 4 cycles of concurrent chemoradiotherapy.

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
DRUG	PD-1 antibody	a new treatment drug combined radical radiotherapy concurrent chemotharpy

Timeline

• Start date: 2020-05-08
• Primary completion: 2021-12-31
• Completion: 2022-12-31
• First posted: 2020-04-29
• Last updated: 2020-04-29

Locations

1 site across 1 country: China